,_
`.
`grog“-tiU1lugr0i"l1t401~t
`January 21, 2014
`
`Johnson & Johnson Reports 2013 Fourth-Quarter and Full-Year Results:
`
`2013 Fourth-Quarter Sales of $18.4 Billion increased 4.5%; EPS was $1.23
`2013 Full-Year Sales of $71.3 Billion increased 6.1%; Full-Year EPS was $4.81
`Excluding Special items, 2013 Fourth-Quarter EPS was $1.24, an increase of 4.2%‘
`And 2013 Full-Year EPS was $5.52. an increase of 8.2%‘
`
`
`
`NEW BRUNSWICK, N.J., Jan. 21, 2014 /PRNewswire/ - Johnson & Johnson (NYSE: JNJ) today announced sales of $18.4 billion for the fourth quarter of 2013, an
`increase of 4.5% as compared to the fourth quarter of 2012. Operational results increased 6.3% and the negative impact of currency was 1.8%. Domestic sales
`increased 7.4%. while international sales increased 2.4%, reflecting operational growth of 5.6% and a negative currency impact of 3.2%. Worldwide sales for the full-
`year 2013 were $71.3 billion. an increase of 6.1% versus 2012. Operational sales increased 7.7% and the negative impact of currency was 1.5%. Domestic sales
`increased 7.0%, while intemalional sales increased 5.4%, reflecting operational growth of 8.2% and a negative currency impact of 2.8%. Sales for the full year included
`the acquisition of Synthes. Inc. which was completed in June 2012. Excluding this impact. net of the divestiture of the DePuy trauma business. worldwide operational
`sales growth was 5.2%.
`
`Net eamings" and diluted earnings per share for the fourth quarter of 2013 were $3.5 billion and $1.23. respectively. Fourth-quarter 2013 net earnings included after-
`tax special items of $42 million, primarily related to an increase in the litigation accrual. an in-process research and development charge, integration and transaction
`costs related to the acquisition of Synthes. Inc., and program costs associated with the DePuy ASRN Hip, offset by a tax benefit associated with Sclos, inc. Fourth-
`quarter 2012 net earnings reflect after-tax special items of $0.8 billion as detailed in the accompanying reconciliation of non-GAAP financial measures. Excluding these
`special items, net earnings for the quarter were $8.6 billion and diluted earnings per share were $1.24, representing increases of 5.5% and 4.2%. respectively, as
`compared to the same period in 2012.‘
`
`Net earnings" and diluted eamlngs per share for the full-year 2013 were $13.8 billion and $4.81, respectively. Full-year net earnings reflect alter-tax special items of
`$2.0 billion in 2013 and $3.5 billion in 2012 as detailed in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items in both
`periods. net earnings for the full-year of 2013 were $15.9 billion and diluted earnings per share were $5.52, representing increases of 10.7% and 8.2%, respectively, as
`compared with the full year of 2012.‘
`
`"Johnson & Johnson delivered strong results in 2013 led by the outstanding performance in our Pharmaceutical business, the strength of key brands in our US OTC
`and other Consumer businesses and continued progress in integrating Synthes into our Medical Devices and Diagnostics business. We also advanced our longer term
`growth drivers, bringing innovative solutions to the global healthcare market and executing with excellence“, said Alex Gorsky, Chairman and Chief Executive Officer.
`‘I
`am proud of our exceptional Johnson & Johnson colleagues for their commitment to leading with purpose and advancing health and well-being for patients and
`consumers around the world."
`
`The Company announced earnings guidance for full-year 2014 of $5.75 to $5.85 per share, which excludes the impact of special items.
`
`Worldwide Consumer sales of $14.7 billion for the full-year 2013 represented an increase of 1.7% versus the prior year. consisting of an operational increase of 2.8%
`and a negative impact from currency of 1.1%. Domestic sales increased 2.3%; international sales increased 1.4%, which reflected an operational increase of 3.1% and
`a negative currency impact of 1.7%.
`
`Positive contributors to operational results were U.S. sales of TYLENOL® and MOTRlN® analgesics; upper respiratory over-the-counter products; international sales of
`baby care products; sales of NEUTROGENA® and AVEENO® skin care products; and intemational sales of LISTERlNE® oral care products.
`
`Worldwide Phannaceutical sales of $28.1 billion for the full-year 2013 represented an increase of 10.9% versus the prior year with an operational increase of 12.0%
`and a negative impact from currency of 1.1%. Domestic sales increased 12.3%; international sales increased 9.6%. which reflected an operational increase of 11.8%
`and a negative currency impact of 2.2%.
`
`Primary contributors to operational sales growth were REMlCADE® (lnfliximab) and SlMPON|®(go|imumab), biologics approved for the treatment of a number of immune-
`mediated inflammatory diseases: STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis;
`lNVEGA® SUSTENNA®/XEPLiON® (paliperidone palmilate), a once-monthly. long-acting, injectable atypical antipsychotlc for the treatment of schizophrenia in adults;
`PREZlSTA® (darunavir). a treatment for HIV; DOXlL® (cioxorubicln HCI liposome injection)/CAELYX® (pegylated iiposomal doxorubicin hydrochloride). a medication to
`treat recurrent ovarian and other cancers; VELCADE® (bortezomib). a treatment for multiple myeloma; and sales of new products.
`
`The strong sales results of new products included ZYTlGA® (abiraterone acetate). an oral, once-daily medication for use in combination with prednlsone for the
`treatment of metastatic, castration-resistant prostate cancer: XARELTO® (rivaroxaban), an oral anticoagulant; the combined sales of COMPLERA®/EViPLERA®
`(emtncitabine /rilpivirine/tenofovir disoproxii fumarate) and EDURANT® (rilpivirine) for the treatment of HIV and iNVOKANA® (canagliflozin) for the treatment of adults with
`type 2 diabetes.
`
`Sales results were negatively impacted by loss of exclusivity for AClPHEX®/ PARiET® (rabeprazole). a proton pump inhibitor for gastrointestinal disorders and
`CONCERTA® lmethylphenidate HCI) for the treatment of attention deficit hyperactivity disorder.
`
`During the quarter, the U.S. Food and Drug Administration (FDA) granted approval of OLYSION (simeprevir) for combination treatment of chronic hepatitis C. The FDA
`also approved IMBRUVICAN (ibrutinib) to treat mantle cell lymphoma for patients who received at least one prior treatment. The European Commission approved
`lNVOKANA® (canagliflozin) for the treatment of adults with type 2 diabetes.
`In addition, SiRTURO® (bedaquiline) received a positive opinion from the European
`Committee for Medicinal Products for use as part of combination therapy to treat adults with pulmonary multi-drug resistant tuberculosis.
`
`A Marketing Authorization Application was submitted to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory
`chronic Iymphocytic leukemia/small Iymphocytic lymphoma or relapsed or refractory mantle cell lymphoma. Also filed with the EMA. was a once-daily single tablet fixed-
`dose antiretroviral combination product containing darunavir, a protease inhibitor developed by Janssen-Cilag International NV marketed as PREZlSTA®, with cobicistat,
`a pharrnacokinetic boosting agent, developed by Gilead Sciences. Inc. for use in combination with other HIV medicines.
`
`Worldwide Medical Devices and Diagnostics (MD&D) sales of $28.5 billion for the full-year 2013 represented an increase of 3.9% versus the prior year with an
`operational increase of 6.1% and a negative impact from currency of 2.2%. Domestic sales increased 3.5%.
`international sales increased 4.2%, which reflected an
`JANSSEN EXHIBIT 2034
`
`Mylan v. Janssen IPR2016-01332
`
`JANSSEN EXHIBIT 2034
`Mylan v. Janssen IPR2016-01332
`
`

`

`operational increase of 8.3% and a negative currency impact of4.1%. Sales included the impact of the acquisition of Synthes, lnc., net of the divestiture of the Del-°uy
`trauma business. Excluding this impact, worldwide MD&D operational sales growth was 0.1%.
`
`Primary contributors to operational growth were sales from the acquisition of Synthes, Inc. and joint reconstruction products in the Orthopaedics business: Blosense
`Webster's electrophysiology products in the Cardiovascular Care business; the Vision Care business; as well as biosurgicals and international sales of energy products
`in the Specialty Surgery business.
`
`\
`
`About Johnson & Johnson
`
`Caring for the world. one person at a time, inspires and unites the people of Johnson 8. Johnson. We embrace research and science — bringing innovative ideas,
`products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 275 Johnson & Johnson operating
`companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
`
`' Net earnings" and diluted earnings per share. excluding special items, are non-GAAP financial measures and should not be considered replacements for, and should
`be read together with, the most comparable GAAP financial measures. A reconciliation of these non—GAAP financial measures to the most directly comparable GAAP
`financial measures is included in the financial schedules accompanying this press release and can be found in the Investor Relations section of the Company's website
`at .
`
`"* Net earnings and diluted earnings per share attributable to Johnson & Johnson.
`
`Johnson 8. Johnson will conduct a meeting with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors
`and other interested parties may be accessed by visiting the Johnson 8. Johnson website at www investor ni ggm. A replay and podcast will be available approximately
`two hours after the live webcast by visiting wvvw,igve§tgr.'ni,com.
`
`Copies of the financial schedules accompanying this press release are available at www investor 'n‘ gom/historigal-sales cfm. These schedules include supplementary
`sales data. a condensed consolidated statement of earnings, reconciliation of non-GAAP financial measures, and sales of key products/franchises. Additional
`information on Johnson 8 Johnson, including a pharmaceutical pipeline of selected compounds in late stage development can be found on the Company's website at
`yyflw ‘nvestgr 'n’|.cgm.
`
`NOTE TO INVESTORS
`
`(This release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these
`forward-looking statements. These statements are based on current expectations of future events.
`lf underlying assumptions prove inaccurate or unknown risks or
`uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson 81 Johnson. Risks and uncertainties include, but are not
`limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new
`products and patents attained by competitors: challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents;
`significant adverse litigation or government action; impact of business combinations; financial distress and bankruptcies experienced by significant customers and
`suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny
`of the health care industry by government agencies; changes in behavior and spending patterns of purchasers of health care products and services: financial instability
`of international economies and sovereign risk: disruptions clue to natural disasters; manufacturing difficulties or delays; complex global supply chains with increasing
`regulatory requirements: and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks,
`uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30. 2012. Copies of
`this Form 10-K. as well as subsequent filings, are available onllne at or on request from Johnson 8 Johnson.
`Johnson & Johnson
`does not undertake to update any forward-looking statements as a result of new information or future events or developments.)
`
`Johnson 8. Johnson and Subsidiaries
`Supplementary Sales Data
`
`(Unaudited: Dollars in Millions) FOURTH QUARTER
`
`Percent Change
`Operations
`
`2013
`
`2012
`
`Total
`
`Currency
`
`
`
`
`TWELVE MONTHS
`Percent Change
`Operations
`
`2013
`
`2012
`
`Total
`
`Currency
`
`Sales to customers by
`segment of business
`Consumer
`U.S.
`international
`
`Pharmaceutical
`US.
`lntemationai
`
`Med Devices & Diagnostics
`US.
`International
`
`U8.
`International
`Worldwide
`
`5 1,263
`2.490
`3,753
`
`3,551
`3,745
`7,286
`
`3,200
`4.106
`7,306
`
`8.014
`10.341
`5 18.355
`
`1.203
`2.449
`3,652
`
`3.013
`3.512
`6.525
`
`3.244
`4,137
`7,381
`
`7,480
`10.098
`17.558
`
`"/u
`
`5.0
`1.7
`2.8
`
`17.9
`6.6
`11.8
`
`(1.4)
`0.7
`1.0
`
`7.4
`2.4
`4.5
`
`"/5
`
`5.0
`4.1
`4.4
`
`17.9
`9.0
`13.1
`
`(1.4)
`3.7
`1.5
`
`7 4
`5.6
`6.3
`
`-
`(2.4
`(1.6
`
`-
`(2.4)
`(1.3
`
`-
`4.4
`(2.5
`
`-
`3.2
`(1.8)
`
`5 5,162
`9,535
`14.697
`
`13.948
`14.177
`28,125
`
`12.300
`15,690
`28,490
`
`31.910
`35.402
`3 71,312
`
`5.046
`5.401
`14.447
`
`12.421
`12.930
`25,351
`
`12.363
`15,063
`27,426
`
`29.830
`37.394
`67,224
`
`2.3
`1.4
`1 7
`
`12.3
`9.6
`10.9
`
`3.5
`4 2
`3.9
`
`7.0
`5.4
`6.1
`
`"/u
`
`"/a
`
`2.3
`3.1
`2.8
`
`12.3
`11.8
`12.0
`
`3.5
`8.3
`6.1
`
`7.0
`8.2
`7.7
`
`-
`(1.7
`(1.1
`
`»
`(2.2)
`1.1
`
`-
`4.1)
`2.2
`
`-
`(2.8
`(1.6)
`
`Johnson E Johnson and Subsidiaries
`Supplementary Sales Data
`
`(Unaudited: Dollars in Milians)
`FOURTH QUARTER
`TWELVE MONTHS
`Percent Change
`Percent Change
`Operations
`Operations
`
`2013
`
`2012
`
`Total
`
`Currency
`
`2013
`
`2012
`
`Total
`
`Currency
`
`

`

`Sales to customers by
`geographic area
`
`
`
`
`
`
`
`
`
`
`
` US. 5 8.014 7.460 7.4 ‘/u 7 4 - $ 31.510 29,830 7.0 "/n 7.0 ~
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Europe
`Western Hemisphere excluding U 8.
`Asia-Pacific, Africa
`international
`
`4,968
`1.891
`3,482
`10,341
`
`4.603
`1,941
`3.554
`10,098
`
`7.9
`(2 6)
`(2.0)
`2.4
`
`Woddwide
`
`$18,355
`
`$17,558
`
`4.5
`
`“.1:
`
`4 8
`4.8
`7.0
`5,6
`
`6 3
`
`3.1
`(7.4)
`(9.0)
`(3 2)
`
`(1.8)
`
`2.1
`7.7
`9.8
`16,945
`18,599
`(5.9)
`8.9
`3 0
`7.207
`7,421
`(7.5)
`8.6
`1.1
`13.242
`13.382
`(2.8)
`8.2
`5 4
`37,394
`39,402
`
`5 71.312
`5 67,224
`6.1
`11.
`7.7
`(1.6)
`
`Johnson 5. Johnson and Subsidiaries
`Condensed Consolidated Statement ot Earnings
`
`(Unaudited: in Millions Except Per Share Figures)
`
`Sales to customers
`Cost of products sold
`Selling, marketing and administrative expenses
`Research and development expense
`In-process research and development
`interest (income) expense, net
`Other income ox ense, net
`Earnings before provision for taxes on income
`Provision torl Benefit from taxes on income
`Net earnings
`Add: Net loss attributable to noncontrolling Interest
`Net earnings attributable to Johnson 5. Johnson
`
`Net earnings per share attributable to Johnson & Johnson (Diluted)
`
`Average shares outstanding (Diluted)
`
`Effective tax rate
`
`2013
`
`Percent
`to Sales
`100.0
`32.5
`32.2
`13.1
`1.9
`0.6
`4.7
`15.0
`(4.2)
`19.2
`~
`19.2
`
`Amount
`$18,355
`5.355
`5,917
`2.411
`338
`115
`868
`2,750
`769)
`3.519
`-
`8 3.519
`
`S
`
`1.23
`
`2,872.0
`
`FOURTH QUARTER
`
`2012
`
`Amount
`3 17,558
`6,003
`5,661
`2.331
`55
`B9
`319
`3.100
`533
`2,567
`~
`S 2,567
`
`S
`
`0.91
`
`2,833.4
`
`(28.0)
`
`‘I.
`
`17.2
`
`‘V.
`
`Percent
`to sales
`100.0
`34.2
`32.2
`13.3
`0.3
`0.5
`1.8
`17.7
`3.1
`14.8
`~
`14.6
`
`Percent
`increase
`(Decrease)
`4 5
`(0.8)
`4.5
`3.4
`
`(11.3)
`
`37.1
`
`37.1
`
`35.2
`
`
`
`Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson (1)
`
`3 4,115
`23.4
`(5.0)
`Earnings before provision tor taxes on income
`S 3,909
`21.3
`3 3,376
`19.2
`5.5
`Net earnings attributable to Johnson 8- Johnson
`3 3,561
`19.4
`Net earnings per share attributable to Johnson 5. Johnson (Diluted)
`5
`1.24
`S
`1.19
`4.2
`‘/.
`‘I.
`Effective tax rate
`8.9
`18.0
`
`
`(1) See Reconciliation of Non~GAAP Financial Measures.
`
`
`
`Johnson 8. Johnson and Subsidiaries
`Condensed Consolidated Statomant of Earnings
`
`(Unaudited; in Millions Except Per Share Figures)
`
`TWELVE MONTHS
`
`2013
`
`2012
`
`Percent
`Increase
`(Decrease)
`6.1
`32
`4.6
`6.8
`
`Percent
`Percent
`to Sales
`Amount
`to Sales
`Amount
`100.0
`5 67,224
`100.0
`9 71.312
`Sale: to customers
`32.2
`21,658
`31.3
`22,342
`Cost of products sold
`31.0
`20.809
`30.6
`21.830
`Selling, marketing and administrative expenses
`11.4
`7,665
`11.5
`0,183
`Research and development expense
`1.7
`1.163
`0.8
`580
`in-process research and development
`0.7
`468
`0.6
`408
`interest (income) expense. net
`2.5
`1,626
`3.5
`2,498
`other (income) expense. net
`12.3
`20.5
`13,775
`21.7
`15,471
`Earnings before provision for taxes on income
`(49.7)
`4.9
`3.261
`2.3
`1,640
`Provision for taxes on income
`31.5
`15.6
`10,514
`19.4
`13,831
`Net earnings
`0.5
`339
`-
`-
`Add: Net loss attributable to noncontroiiin interest
`_%?%
`Net earnings attributable to Johnson ii. Johnson
`$13,831
`19.4
`510,853
`16.1
`27.4
`
`_
`
`Net earnings per share attributable to Johnson 8 Johnson (Diluted)
`
`Average shares outstanding (Diluted)
`
`Eflective tax rate
`
`S
`
`4.81
`
`2,877.0
`
`S
`
`3.86
`
`2,812.8
`
`10.6
`
`‘I.
`
`23.7 %
`
`24.6
`
`Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson (1)
`
`
`3 18.214
`27.1
`5.2
`Earnings before provision for taxes on income
`$19,169
`26.9
`
`
`$14,345
`21.3
`10.7
`Net earnings attributable to Johnson 0. Johnson
`$15,876
`22.3
`
`
`Net earnings per share attributable to Johnson 8- Johnson (Diluted)
`S
`5.52
`S
`5.10
`8.2
`Effective tax rate
`17.2
`21.2
`‘A
`“I.
`
`
`

`

`(1) See Reconciliation of Non-GAAP Financial Measures.
`
`Johnson at Johnson and Subsidiaries
`Reconciliation of Non~GAAP Financial Measures
`
`(Dollars in Millions Except Per Share Data)
`
`Fourth Quarter
`2013
`2012
`
`% lncr, /
`(Dec!)
`
`Twelve Months
`2013
`2012
`
`°/u tncr. /
`(Dean)
`
`Earnings belore provision for taxes on income « as reported
`
`3 2.750
`
`3.100
`
`(11.3)
`
`‘if:
`
`Litigation expenses
`
`ln-process research and development
`
`Synthes integration/transaction costs and currency related
`
`DePuy ASR'" Hip program
`
`intangible asset write-downs
`
`Other
`
`Earnings before provision lor taxes on Income - as adjusted
`
`Net Earnings attributable to Johnson & Johnson - as reported
`
`Litigation expenses
`
`in-process research and development
`
`Synthes integration/transaction costs and currency related
`
`DePuy ASR” Hip program
`
`506
`
`338
`
`181
`
`134
`
`-
`
`.
`
`5 3.909
`
`$ 3.519
`
`227
`
`294
`
`110
`
`118
`
`471
`
`55
`
`406
`
`83
`
`»
`
`.
`
`4.115
`
`2,567
`
`371
`
`59
`
`306
`
`73
`
`-
`
`(5.0) %
`
`37.1
`
`‘V:
`
`12.3 %
`
`5,2
`
`27.4
`
`“/9
`
`"In
`
`3 15.471
`
`2,262
`
`560
`
`553
`
`251
`
`-
`
`(98)
`
`$19,169
`
`$13 831
`
`1.646
`
`462
`
`483
`
`240
`
`—
`
`13.775
`
`1.229
`
`1.163
`
`1.028
`
`110
`
`939
`
`(30)
`
`15.214
`
`10,853
`
`1.052
`
`743
`
`899
`
`97
`
`717
`
`(1)
`
`intangible asset write—downs
`
`Scios Tax Benefit
`
`Other
`
`Net Earnings attributable to Johnson 8. Johnson - as adjusted
`
`Diluted Net Earnings per share attributable to Johnson 8: Johnson - as reported
`
`Litigation expenses
`
`in-process research and development
`
`Synlhes integration/transaction costs and currency related
`
`DePuy ASR” Hip program
`
`intangible asset write-downs
`
`Scios Tax Benefit
`
`Other
`
`~
`
`(707)
`
`~
`
`S 3.561
`
`S 1 23 .
`
`0 08
`
`0.10
`
`0 04
`
`0.04
`
`-
`
`(0.25)
`
`-
`
`-
`
`~
`
`3.376
`
`0.91
`
`0.13
`
`0.02
`
`0,11
`
`0.02
`
`-
`
`—
`
`-
`
`5 5
`
`"/o
`
`35.2 %
`
`(707)
`
`179)
`
`3 15.876
`
`$
`
`4.81
`
`0.57
`
`0.16
`
`0.17
`
`0.08
`
`»
`
`(0.25)
`
`(0.02)
`
`Diluted Net Earnings per share attributable to Johnson & Johnson - as adjusted
`
`5 1.24
`
`1.19
`
`4.2
`
`"‘/u
`
`3
`
`5.52
`
`-
`
`(15)
`
`14.345
`
`3.85
`
`0.37
`
`0.27
`
`0.32
`
`0.03
`
`0.26
`
`-
`
`(0.01)
`
`5.10
`
`10.7
`
`24.6
`
`"/a
`
`‘'/n
`
`8.2
`
`‘In
`
`(1)Amount includes third quarter in-process research and development charge of $679M related to bapineuzumab IV ofiset by $339M reported as net loss attributable to noncontroiling interest
`
`The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings beiore provision for taxes on income. net earnings and diluted net eamings
`per share that excludes special items in order to evaluate ongoing business operations.
`
`FOURTH QUARTER
`
`TWELVE MONTHS
`
` fl@
`A Y EAR
`US
`lntl
`
`ORAL QARE
`US
`lnli
`WW
`91219
`
`-0.1%
`
`2_01_2
`
`fZ3p_9_(_t_g_q Qperatiogg] 111 ggrrongx
`
`0.2%
`2.2%
`1.8%
`
`-6.1%
`3.8%
`
`

`

`US
`11111
`ww
`SKIN §AB§
`us
`11111
`w
`WOMEN'S HEALTH
`us
`Inn
`w
`wogmo gARg;oTHER #9
`us
`11111
`ww
`
`mE
`us
`11111
`w
`
`332
`747
`1,079
`
`432
`533
`910
`
`as
`310
`343
`
`203
`150
`353
`
`1.253
`2.490
`3.753
`
`5
`
`273
`743
`1,018
`
`3135
`509
`594
`
`1:2
`325
`407
`
`195
`152
`347
`
`1,203
`2.449
`3,552
`
`2115%
`0.5%
`6.2%
`
`12 2%
`5.7%
`5.5%
`
`-53.71%
`4.5%
`.14 5%
`
`4.1%
`-1.3%
`1.7%
`
`5.0%
`1.1%
`2.a%
`
`-1.5-/.
`
`21.6%
`1.1%
`6.6%
`
`12.2%
`7.4%
`9.5%
`
`—s3.7%
`-0.5%
`.11.5%
`
`4.1%
`0.5%
`2.5%
`
`5.0-/.
`4.1‘/.
`4.4-/.
`
`—
`.o,6%
`-0.4%
`
`-
`-1.7%
`-1.0%
`
`-
`-3.8%
`4.0%
`
`-
`-1.9%
`-0.9%
`
`-
`-2.4%
`
`See footnotes at end at schedule
`
`T
`
`o
`
`M
`
`
`
`TWELVE Moms
`
`
`
`9.190
`
`1,a74
`
`16.7%
`
`17.5%
`
`-0.5%
`
`3.391
`1,339
`1,443
`5,573
`
`4114
`523
`932
`
`957
`541
`1,5114
`
`.
`a1
`a1
`
`1,o77
`2.473
`3,551.1
`
`-
`517
`511
`
`157
`192
`379
`
`607
`use
`
`3.59:
`1,471:
`was
`5,139
`
`292
`315
`e07
`
`521
`29:
`1.025
`
`.
`10:
`1113
`
`974
`2.220
`3,194
`
`.
`44:
`44:
`
`175
`173
`349
`
`572
`742
`
`am
`.e,9%
`32.9%
`5.7%
`
`313.4%
`57.5%
`535%
`
`52.6%
`37.4%
`45.7%
`
`.
`.21.4%
`.214%
`
`10.6%
`11.4%
`11.1%
`
`-
`15.7%
`16.7%
`
`6.3%
`11.0%
`8.6%
`
`20.1%
`15.7%
`
`a 5%
`-3.9%.
`36.2%
`9.3%
`
`38.4%
`75.1%
`57.4%
`
`52.5%
`321.3%
`47.0%
`
`.
`.1a.s%
`45.5%
`
`10.5%
`11.5%
`11.1%
`
`-
`17.5%
`17.5%
`
`6.3%
`1o.a%
`5.5%
`
`20.1%
`15.2%
`
`.
`.
`-3.3%
`.o.s%
`
`.
`75%
`41.9%
`
`.
`-0.9%
`-0.3%
`
`.
`2.9%
`.2 9%
`
`.
`-0.1%
`o.o%
`
`.
`.o.a%
`.o.e%
`
`.
`0.2%
`0.1%
`
`.
`0.5%
`
`R§PORT§D §A§,ES vs, PBJOR PQRIQQ (§MM]
`
` W
`IMMUNQLQQY
`us
`Inn
`ww
`
`ReM1gA1:>g
`us
`us Experts (5)
`11111
`ww
`§.Lt:1B2fl1
`us
`mm
`w
`§IE.LABA
`us
`11111
`w
`gmgsz mmggwo ocv
`us
`11111
`ww
`M
`us
`11111
`w
`
`111911/Q
`us
`11111
`w
`lmgggugg
`us
`11111
`w
`paszxgm
`us
`1111
`
`w O
`
`THER [NFEQTQQUS DI§§A§§§
`US
`Int!
`WW
`
`
`US
`
`FOURTH QUARTER
`
`"/1. Chan 1 a
`201;
`2912
`RJp_g_13_eg Ogurgjlgnagm ggrrgngy
`
`
`TWELVE MONTHS
`
`.
`§g_gp_g_r19_g Opgratignalm Cugrency
`
`201;
`
`2g1g
`
`2.584
`
`2.611
`
`NE R
`
`NC
`
`

`

`imi
`W
`§;ON§;_fiRT3[M§THYL_EH§N|QAT§
`US
`ml!
`W
`|N\l§§A
`US
`lntl
`W
`NV§§§A SUSTENNAI XEPL ON
`US
`Inn
`W
`BI§EE.BDAL_C_O£L'5_IA
`US
`Int!
`WW
`H
`
`R
`
`5
`
`US
`lntl
`W
`QMEQLQEI
`US
`Int!
`W
`
`VEL§AQ§
`US
`Int!
`W
`$195
`US
`Int]
`WW
`OTHER ONCQLOGY
`US
`IN!
`W
`
`TOTALOTHER
`US
`M11
`WW
`
`Ag; PHEXIPARQE
`US
`Inll
`WW
`F‘RQ§R T[§FRfiX
`US
`Int!
`W
`X_AE§LTO
`US
`Int!
`W
`OTHER
`US
`Int!
`WW
`
`4.053
`6,667
`
`308
`474
`782
`
`318
`267
`583
`
`690
`558
`1,248
`
`440
`B78
`1,318
`
`830
`1.906
`2,736
`
`E48
`2,925
`3,773
`
`-
`1.660
`1,660
`
`750
`943
`1,698
`
`93
`317
`415
`
`4.107
`6.718
`
`609
`464
`1,073
`
`299
`251
`550
`
`482
`314
`796
`
`435
`986
`1,425
`
`782
`2.092
`2.874
`
`505
`2.123
`2,829
`
`-
`1,500
`1,500
`
`463
`498
`BS1
`
`43
`125
`186
`
`-0.6%
`-(16%
`
`-49.4%
`2.2%
`v27.1%
`
`5 7%
`6 4%
`6.0%
`
`43.2%
`717%
`56.8%
`
`0 2%
`-11 0%
`-7.5%
`
`611%
`~8 9%
`-4.8%
`
`67 6%
`318%
`43.5%
`
`~
`10.7%
`10 7%
`
`62 0%
`90.4%
`75‘-7°/u
`
`’
`‘
`‘
`
`3.4%
`1.6%
`
`49.4%
`5.0%
`-259%
`
`5.7%
`121351’:
`8.7%
`
`43.2%
`75.8%
`56.4%
`
`0.2%
`-8.7%
`~5.9°/a
`
`6.1%
`-3.3%
`-0.7%
`
`67 6%
`39.7%
`45.0%
`
`-
`13.6%
`13.6%
`
`52109:
`88.4%
`75.6%
`
`’
`'
`'
`
`-4.0%
`-2.4%
`
`-
`~2.8“/2
`-1.2%
`
`-
`-5.9%
`-27%
`
`-
`0.9%
`0.4%
`
`-
`-23%
`-1.6%
`
`-
`-5.6%
`-4.1%
`
`-
`-1.9%
`-15%
`
`~
`-2.9%
`-2.9%
`
`-
`2.0%
`1.1%
`
`—
`-2.2%
`4.7%
`
`R
`
`R
`
`SA
`
`V
`
`P
`
`RP
`
`D MM
`
`2
`
`2
`
`Ragortnd Ogarafionalm Cgrrancx
`17.4%
`17.4%
`47.2%
`-16.4%
`0 1%
`0.5%
`
`"/.Chana
`Ragorlog Ogotatlogalm Cgrrgngx
`20,,8"/a
`20 8%
`-18.7%
`-18 2%
`0.2%
`05%
`
`-28.8%
`-55.7%
`-417“/a
`
`—12%
`-13.4%
`-6.7%
`
`-28.8“/a
`-$5.5“/a
`-43.6"/o
`
`>1 2%
`44.0%
`-7.0%
`
`864
`.
`864
`
`924
`1,323
`2,247
`
`13,948
`14,177
`28,125
`
`5
`
`12.421
`12.930
`=——-2-
`25,351
`
`R
`
`5
`
`S
`
`O
`
`FOURTH QUARTER
`
`I
`
`TWELVE MONTHS
`
`TOTAL PflAgMAC§U 1 ICAL,
`US
`Int!
`W
`
`Sea footnotes at and of schedule.
`
`3,013
`3.512
`6,525
`
`

`

`M§D|§A;, ggvrggg Aug glgguosngg E1
`QARQKJVASCULAR cm;
`us
`um
`w
`l2tA§EIE§.;Al3_E
`us
`1m:
`w
`omowosncg
`us
`mu
`w
`INFEQT QN PREVENT Q[g[§QTHfi5
`us
`run
`w
`0RTHOPA§DlCS
`us
`mu
`ww
`sp cm rv suns RY
`us
`mu
`w
`R
`
`cm:
`
`us
`lntl
`ww
`VI§lQN gmg
`us
`mu
`w
`
`s
`
`221.:
`
`210
`324
`5:14
`
`219
`:44
`563
`
`215
`251
`ass
`
`so
`155
`246
`
`1,307
`1.149
`2.455
`
`3:12
`351
`as:
`
`599
`1.040
`1,539
`
`225
`491
`119
`
`[QTAL MEDICAL DEVIQES AND DIAGNOSTICS
`US
`lntl
`W
`
`3,200
`4.106
`7.306
`
`5
`
`135
`320
`505
`
`295
`349
`644
`
`253
`272
`sao
`
`as
`1511
`245
`
`1.245
`1.142
`2.335
`
`325
`:29
`ass
`
`6111
`1.049
`1.667
`
`229
`515
`745
`
`3,244
`4.137
`7.381
`
`‘ Percentage greater than 100%
`(1) Operational growth excludes the effect of currency
`(2) Unaudited
`(3) Nutntlonals now reflected In Wound Care/Other. previously reported in OTC/Nutritlonals
`(4) Prior year amounts have been reclassified to conform to current year product disclosure
`(5) Reported as US. sales
`
`SOURCE Johnson 8. Johnson
`
`News Provided by Acquire Media
`
`3131
`551
`912
`
`5.1174
`4.435
`9.509
`
`1,30:
`1,2119
`2.592
`
`2.294
`3,975
`5.259
`
`1.035
`1.901
`2,937
`
`12,800
`15.690
`28,490
`
`5
`
`12,383
`15.063
`===a%
`21,426
`
`

`

`